Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. The established therapeutic regimen includes a tripartite therapy of surgical resection followed by radiation and temozolomide (TMZ) chemotherapy, concurrently with radiatio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sadhak Sengupta, Jaclyn Marrinan, Caroline Frishman, Prakash Sampath
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	Clinical and Developmental Immunology
Online Access:	http://dx.doi.org/10.1155/2012/831090
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-κB Pathway
by: Jen-Tsung Yang, et al.
Published: (2017-01-01)

Prolonged Remission in Metastatic Ano‐Rectal Malignant Melanoma With Single Agent Temozolomide
by: Anusha Mruthyunjaya Swamy, et al.
Published: (2025-01-01)

Temozolomide-Induced Myelodysplasia
by: Ethan A. Natelson, et al.
Published: (2010-01-01)

The Controversial Role of Microglia in Malignant Gliomas
by: Jun Wei, et al.
Published: (2013-01-01)

Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.
by: Artem Berezovsky, et al.
Published: (2025-01-01)

Malignant Glioma in the Cerebellum Presenting as Multiple Small Lesions
by: Takashi Mamiya, et al.
Published: (2019-01-01)

Fluorescence-Guided Resection of Malignant Glioma with 5-ALA
by: Sadahiro Kaneko, et al.
Published: (2016-01-01)

Predicting survival in malignant glioma using artificial intelligence
by: Wireko Andrew Awuah, et al.
Published: (2025-01-01)

Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
by: Yuanyuan Chen, et al.
Published: (2025-02-01)

A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma
by: Ana Misir Krpan, et al.
Published: (2017-01-01)

Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide
by: Erkan Topkan, et al.
Published: (2022-01-01)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
by: Ingrid H. Olsen, et al.
Published: (2012-01-01)

A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment
by: Haruko Morokuma, et al.
Published: (2012-01-01)

Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients
by: Zhaoyue Yan, et al.
Published: (2022-01-01)

A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy
by: Dong-Sup Chung, et al.
Published: (2014-01-01)

Magnetic and pH sensitive nanocomposite microspheres for controlled temozolomide delivery in glioblastoma cells
by: Meysam Ahmadi, et al.
Published: (2024-12-01)

Synergism of d-limonene and temozolomide on migratory and apoptotic behaviors of human glioblastoma cell lines
by: Megha Gautam, et al.
Published: (2024-09-01)

Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
by: Farhan Ashraf, et al.
Published: (2016-01-01)

Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases
by: Yi-Hsin Liang, et al.
Published: (2013-01-01)

Identification and Validation of TEAD Family’s Prognostic Effects and Immune Microenvironment Regulations in Glioma
by: Zhengyuan Huo, et al.
Published: (2024-01-01)

Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database
by: Hanzhang Yuan, et al.
Published: (2025-01-01)

Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
by: Oscar D. Bruno, et al.
Published: (2015-01-01)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
by: Noel J. Aherne, et al.
Published: (2014-01-01)

Advanced Epithelioid Malignant Peripheral Nerve Sheath Tumor Showing Complete Response to Combined Surgery and Chemotherapy: A Case Report
by: Tomohiro Minagawa, et al.
Published: (2011-01-01)

Impact of Metabolism on Immune Responses
by: Abdallah Elkhal, et al.
Published: (2018-01-01)

Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer
by: Ke Zhu, et al.
Published: (2021-01-01)

Identification and validation of TSPAN13 as a novel temozolomide resistance-related gene prognostic biomarker in glioblastoma.
by: Haofei Wang, et al.
Published: (2025-01-01)

Author Correction: Magnetic and pH sensitive nanocomposite microspheres for controlled temozolomide delivery in glioblastoma cells
by: Meysam Ahmadi, et al.
Published: (2025-01-01)

In Situ Thrombosis of Small Pulmonary Arteries in Pulmonary Hypertension Developing after Chemotherapy for Malignancy
by: Kay Maeda, et al.
Published: (2015-01-01)

Congenital Intranasal Glioma
by: Sajad Ahmad Salati, et al.
Published: (2011-01-01)

Optic nerve glioma
by: U. Masilionytė, et al.
Published: (2023-10-01)

Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
by: Lana Bijelic, et al.
Published: (2012-01-01)

Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors
by: Huan Hu, et al.
Published: (2025-01-01)

RETRACTED ARTICLE: Construction and validation of a machine learning-based immune-related prognostic model for glioma
by: Qi Mao, et al.
Published: (2024-10-01)

The MicroRNA-106a/20b Strongly Enhances the Antitumour Immune Responses of Dendritic Cells Pulsed with Glioma Stem Cells by Targeting STAT3
by: Hui Zhou, et al.
Published: (2022-01-01)

An Unusual Long-Term Survey of a Patient with Widespread Malignant Urachal Tumor, Not Given Chemotherapy or Radiotherapy
by: Tugrul Ormeci, et al.
Published: (2015-01-01)

MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway
by: Zigui Chen, et al.
Published: (2025-02-01)

Dihydroartemisinin inhibits EphA2/PI3K/Akt pathway-mediated malignant behaviors and vasculogenic mimicry in glioma stem cells
by: Huangde Fu, et al.
Published: (2025-02-01)

Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification
by: Hong-xin Su, et al.
Published: (2022-01-01)

The impact of innate immune response on the efficacy of oncolytic viruses
by: Kirill N. Trachuk, et al.
Published: (2024-12-01)